155 related articles for article (PubMed ID: 18473752)
21. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
Joerger M; Huitema AD; Boot H; Cats A; Doodeman VD; Smits PH; Vainchtein L; Rosing H; Meijerman I; Zueger M; Meulendijks D; Cerny TD; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2015 Apr; 75(4):763-72. PubMed ID: 25677447
[TBL] [Abstract][Full Text] [Related]
22. [Thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in soft-tissue sarcoma versus capecitabine potential].
Stepanova EV; Bokhian BIu; Petrovichev NN; Lichinitzer MR
Vopr Onkol; 2005; 51(3):314-6. PubMed ID: 16279094
[TBL] [Abstract][Full Text] [Related]
23. Enzyme expression profiles suggest the novel tumor-activated fluoropyrimidine carbamate capecitabine (Xeloda) might be effective against papillary thyroid cancers of children and young adults.
Patel A; Pluim T; Helms A; Bauer A; Tuttle RM; Francis GL
Cancer Chemother Pharmacol; 2004 May; 53(5):409-14. PubMed ID: 15132128
[TBL] [Abstract][Full Text] [Related]
24. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
25. Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Lee SJ; Choi YL; Park YH; Kim ST; Cho EY; Ahn JS; Im YH
Cancer Chemother Pharmacol; 2011 Sep; 68(3):743-51. PubMed ID: 21170649
[TBL] [Abstract][Full Text] [Related]
26. Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy.
Zhao HY; Huang H; Hu ZH; Huang Y; Lin SX; Tian Y; Lin TY
Anticancer Drugs; 2012 Jun; 23(5):534-42. PubMed ID: 22481060
[TBL] [Abstract][Full Text] [Related]
27. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.
Salonga D; Danenberg KD; Johnson M; Metzger R; Groshen S; Tsao-Wei DD; Lenz HJ; Leichman CG; Leichman L; Diasio RB; Danenberg PV
Clin Cancer Res; 2000 Apr; 6(4):1322-7. PubMed ID: 10778957
[TBL] [Abstract][Full Text] [Related]
28. Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival.
Saif MW; Hashmi S; Bell D; Diasio RB
Expert Opin Drug Saf; 2009 Sep; 8(5):507-14. PubMed ID: 19663627
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations.
Queckenberg C; Erlinghagen V; Baken BC; Van Os SH; Wargenau M; Kubeš V; Peroutka R; Novotný V; Fuhr U
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1081-91. PubMed ID: 26242222
[TBL] [Abstract][Full Text] [Related]
30. The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil.
Jensen SA; Vainer B; Sørensen JB
Int J Cancer; 2007 Feb; 120(3):694-701. PubMed ID: 17096352
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
Ouchi KF; Yanagisawa M; Sekiguchi F; Tanaka Y
Cancer Chemother Pharmacol; 2006 May; 57(5):693-702. PubMed ID: 16362295
[TBL] [Abstract][Full Text] [Related]
32. Preoperative radiotherapy and concomitant capecitabine treatment induce thymidylate synthase and thymidine phosphorylase mRNAs in rectal carcinoma.
Kocakova I; Svoboda M; Kubosova K; Chrenko V; Roubalova E; Krejci E; Sefr R; Slampa P; Frgala T; Zaloudik J
Neoplasma; 2007; 54(5):447-53. PubMed ID: 17688376
[TBL] [Abstract][Full Text] [Related]
33. Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer.
Andreetta C; Puppin C; Minisini A; Valent F; Pegolo E; Damante G; Di Loreto C; Pizzolitto S; Pandolfi M; Fasola G; Piga A; Puglisi F
Ann Oncol; 2009 Feb; 20(2):265-71. PubMed ID: 18765464
[TBL] [Abstract][Full Text] [Related]
34. Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome.
Saif MW; Eloubeidi MA; Russo S; Steg A; Thornton J; Fiveash J; Carpenter M; Blanquicett C; Diasio RB; Johnson MR
J Clin Oncol; 2005 Dec; 23(34):8679-87. PubMed ID: 16314628
[TBL] [Abstract][Full Text] [Related]
35. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
Rosmarin D; Palles C; Pagnamenta A; Kaur K; Pita G; Martin M; Domingo E; Jones A; Howarth K; Freeman-Mills L; Johnstone E; Wang H; Love S; Scudder C; Julier P; Fernández-Rozadilla C; Ruiz-Ponte C; Carracedo A; Castellvi-Bel S; Castells A; Gonzalez-Neira A; Taylor J; Kerr R; Kerr D; Tomlinson I
Gut; 2015 Jan; 64(1):111-20. PubMed ID: 24647007
[TBL] [Abstract][Full Text] [Related]
36. Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy.
Nishimura G; Terada I; Kobayashi T; Ninomiya I; Kitagawa H; Fushida S; Fujimura T; Kayahara M; Shimizu K; Ohta T; Miwa K
Oncol Rep; 2002; 9(3):479-82. PubMed ID: 11956613
[TBL] [Abstract][Full Text] [Related]
37. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
Chefrour M; Milano G; Formento P; Giacometti S; Denden A; Renée N; Iliadis A; Fischel JL; Ciccolini J
Fundam Clin Pharmacol; 2012 Aug; 26(4):530-7. PubMed ID: 21623901
[TBL] [Abstract][Full Text] [Related]
38. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.
Sharma R; Hoskins JM; Rivory LP; Zucknick M; London R; Liddle C; Clarke SJ
Clin Cancer Res; 2008 Feb; 14(3):817-25. PubMed ID: 18245544
[TBL] [Abstract][Full Text] [Related]
39. Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889.
Endo M; Miwa M; Eda H; Ura M; Tanimura H; Ishikawa T; Miyazaki-Nose T; Hattori K; Shimma N; Yamada-Okabe H; Ishitsuka H
Int J Cancer; 2003 Sep; 106(5):799-805. PubMed ID: 12866042
[TBL] [Abstract][Full Text] [Related]
40. Capecitabine therapy for refractory metastatic thyroid carcinoma: a case series.
Gilliam LK; Kohn AD; Lalani T; Swanson PE; Vasko V; Patel A; Livingston RB; Pickett CA
Thyroid; 2006 Aug; 16(8):801-10. PubMed ID: 16910885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
